Advertisement
UK markets closed

  • FTSE 100

    8,139.83
    +60.97 (+0.75%)
     

  • FTSE 250

    19,824.16
    +222.18 (+1.13%)
     

  • AIM

    755.28
    +2.16 (+0.29%)
     

  • GBP/EUR

    1.1672
    +0.0015 (+0.13%)
     

  • GBP/USD

    1.2488
    -0.0023 (-0.19%)
     

  • Bitcoin GBP

    50,961.15
    -600.15 (-1.16%)
     

  • CMC Crypto 200

    1,326.30
    -70.23 (-5.03%)
     

  • S&P 500

    5,107.54
    +59.12 (+1.17%)
     

  • DOW

    38,288.67
    +202.87 (+0.53%)
     

  • CRUDE OIL

    83.94
    +0.37 (+0.44%)
     

  • GOLD FUTURES

    2,347.50
    +5.00 (+0.21%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • HANG SENG

    17,651.15
    +366.61 (+2.12%)
     

  • DAX

    18,161.01
    +243.73 (+1.36%)
     

  • CAC 40

    8,088.24
    +71.59 (+0.89%)
     
PROPERTY:

9 luxury homes to consider if money is no object

Ever thought about what a multimillion pound budget would buy you?

Top Stock Picks for the Week of July 22, 2019

Tracey Ryniec

Microsoft MSFT has a great track record of beating on earnings, so no one was surprised when the company did it again in July. It posted a strong fiscal fourth quarter with Commercial Cloud revenue up 39%, led by Azure up 64%. Office 365 now has 34.8 million subscribers and LinkedIn saw record engagement in the quarter. The company is only trading with a forward P/E of 26. It’s a Zacks Rank #2 (Buy) stock. [In full disclosure, Tracey owns shares of Microsoft in her personal portfolio.]

Cintas CTAS beat on the fourth quarter and gave guidance for fiscal 2020 above the Zacks Consensus as the uniform rental business remains strong. It saw strength in healthcare, education and government. It has now posted 9 consecutive years of mid-single digit revenue growth. That’s impressive. Cintas shares are also breaking out to new multi-year highs on the news. It’s a Zacks Rank #2 (Buy) stock.

Should these two companies be on your investing short list? Find out in this week’s video.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Microsoft Corporation (MSFT) : Free Stock Analysis Report
 
Cintas Corporation (CTAS) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research